Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
08 janv. 2018 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce the results of the Special Meeting of Stockholders held on January 5, 2018. ...
Anthera Pharmaceuticals Announces Appointment of Patrick Murphy as Senior Vice President, Manufacturing
03 janv. 2018 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the appointment of Patrick Murphy as Senior Vice President, Manufacturing. Patrick...
Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura
11 déc. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the pre-specified interim futility analysis for the RESULT Phase...
Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal
17 nov. 2017 16h05 HE
|
Anthera Pharmaceuticals, Inc.
Delisting notice was expected as part of the compliance extension previously granted by NasdaqContinue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel HAYWARD,...
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura
09 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of...
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results
06 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
RESULT, Phase 3 clinical study of Sollpura, topline data expected Q1 2018RESULT sanctioned by the European Cystic Fibrosis Society Clinical Trial NetworkBlisibimod granted FDA orphan drug designation...
Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting
05 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional findings from the CHABLIS-SC1, Phase 3 clinical study of blisibimod, a novel...
Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference
02 nov. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that data from the SOLUTION, Phase 3 clinical study of Sollpura (liprotamase) and an...
Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting
01 nov. 2017 17h00 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new data from the CHABLIS-SC1 Phase 3 clinical study of blisibimod, a novel treatment that...
Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering
24 oct. 2017 08h30 HE
|
Anthera Pharmaceuticals, Inc.
HAYWARD, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has entered into a definitive agreement with certain institutional and...